116 results about "Proteoglycan" patented technology

The invention belongs to the technical field of microbial fermentation, and particularly relates to lactobacillus rhamnosus capable of maintaining bone health and improving local joint inflammation and a metagen and application of the lactobacillus rhamnosus. According to the invention, the probiotic NKU ML1-2 is subjected to fermentation culture, such that a post-generation product is prepared. Results of embodiments prove that the metagen product can enhance the oxidation resistance of cartilage and osteoblasts and promote the synthesis of anti-inflammatory factors and cartilage matrixes (type II collagen and proteoglycan), and has the potential of relieving oxidative stress and inflammatory response of local joints, relieving joint inflammation and delaying cartilage destruction. The prepared metagen product is high in safety and good in stability, and can be applied to preparation of medicines for preventing and / or treating osteoarthritis; the metagen product can also be used for promoting bone health, enhancing the antioxidant capacity of osteoblasts and / or chondrocytes, promoting osteoblast activity and / or promoting calcium absorption and fixation, and a new solution is provided for joint health management.

The invention discloses a pharmaceutical composition for promoting angiogenesis and tissue regeneration and application thereof. The pharmaceutical composition of the present invention comprises an acidic secretory protein rich in cysteine, a disaccharide chain proteoglycan, and an XV-type collagen alpha1 chain. The biological material system loaded with the three types of proteins can promote angiogenesis, and can improve the tissue regeneration efficiency of bone, cartilage and skin defect areas.

The growth factor profile, connective tissue matrix constituents, and immunoprivileged status of urodele extracellular matrix (ECM) and accompanying cutaneous tissue, plus the presence of antimicrobial peptides there, render urodele-derived tissue an ideal source for biological scaffolds for xenotransplantation. In particular, a biological scaffold biomaterial can be obtained by a process that entails (A) obtaining a tissue sample from a urodele, where the tissue comprises ECM, inclusive of the basement membrane, and (B) subjecting the tissue sample to a decellularization process that maintains the structural and functional integrity of the extracellular matrix, by virtue of retaining its fibrous and on-fibrous proteins, glycoaminoglycans (GAGs) and proteoglycans, while removing sufficient cellular components of the sample to reduce or eliminate antigenicity and immunogenicity for xenograft purposes. The resultant urodele-derived biomaterial can be used to enhance restoration of skin homeostasis, to reduce the severity, durations and associated damage caused by post-surgical inflammation, and to promote progression of natural healing and regeneration processes. In addition, the biomaterial promotes the formation of remodeled tissue that is comparable in quality, function, and compliance to undamaged human tissue.

The invention relates to the technical field of agricultural fertilizers, in particular to a shiitake mushroom residue functional proteoglycan organic fertilizer as well as a preparation method and an application method thereof. The organic fertilizer is prepared from 40-60% of functional proteoglycan, 15-30% of humic acid, 8-15% of monopotassium phosphate, 5-10% of charcoal and 5-10% of seaweed extract, the functional proteoglycan is prepared by mixing shiitake mushroom residues, oyster mushroom residues and agaric residues, the molecular weight of the functional proteoglycan is 5-50 kDa, and the functional proteoglycan contains a beta-1, 3 / 1, 6-glucan structure; the preparation method comprises the steps of mushroom dreg pretreatment, ultrasonic-assisted enzymolysis, multi-stage membrane separation, concentration and drying, formula mixing, granulation and packaging and the like. The organic fertilizer has dual functions of promoting plant growth and activating a plant immune system, can significantly improve the disease resistance and yield of plants, and improves the physicochemical properties of soil; the preparation process is environment-friendly, high in extraction efficiency and low in energy consumption; and the pH value of the product is adjustable.

The invention relates to the technical field of functional nutritious food, in particular to multi-layer skin nutrition powder with a whole-spectrum skin growth and repair promoting effect and a preparation method and application thereof, the core of the multi-layer skin nutrition powder is composed of a collagen peptide system (60-62%), a proteoglycan system (20-22%) and the like, collagen peptide is compounded with three sources of cattle, fish and chicken, and the multi-layer skin nutrition powder has the advantages that the multi-layer skin nutrition powder is prepared; according to the present invention, with the combination of the following components, the skin structure and activity are jointly promoted by using the synergistic effect of the functional polypeptide compound (2.5-3.5%) and the plant active component (3.5-4.5%) rich in asiaticoside and procyanidine, and the nutrition enhancers (4-5%) such as L-ascorbic acid and amino acid chelated zinc and the food-grade auxiliary materials (8-10%) such as microcrystalline cellulose are integrated in the formula, such that the various systems achieve the synergistic effect so as to achieve the effect of nourishing the skin; through the synergistic compatibility of the three-source collagen peptide, the comprehensive supplement of various types of collagen in skin tissues is realized.

Provided is a method for simply and inexpensively producing a high-purity proteoglycan from a crushed product of cartilage tissue, a squeezed product of the crushed product, or an extract of the crushed product or the squeezed product.　In the present invention, a crushed product of cartilage tissue, a squeezed product of the crushed product, or an extract of the crushed product or the squeezed product is immersed in or added to an aqueous solution containing a salt, and an alcohol is added to the obtained liquid composition in such an amount as to have a final concentration of 10-60 vol%, whereby a proteoglycan is precipitated. Alternatively, a crushed product of cartilage tissue, a squeezed product of the crushed product, or an extract of the crushed product or the squeezed product is immersed in or added to an aqueous solution containing a salt and an alcohol in such an amount as to have a final concentration of 10-60 vol%, whereby a proteoglycan is precipitated.

This invention belongs to the field of functional food processing technology, specifically relating to a method for improving the flavor of a chlorophyll-deficient Chlorella proteoglycan mutant. The method includes the following steps: S1, obtaining a Chlorella proteoglycan mutant strain; S2, centrifuging the Chlorella proteoglycan mutant strain and collecting the algal sludge, then pulverizing the collected algal sludge and dispersing it in water to obtain an algal powder suspension, then adding a compound enzyme to the algal powder suspension, and inactivating the enzyme after the reaction; S3, cooling the system to room temperature, adding glucose and stirring to dissolve, sterilizing, inoculating with a compound bacterial strain and fermenting, and sterilizing again after fermentation; S4, cooling the fermented system to room temperature, then adding β-cyclodextrin and stirring, and drying the system after stirring to obtain the algal protein product. This invention employs a synergistic process of compound enzymatic hydrolysis, compound bacterial fermentation, and β-cyclodextrin encapsulation to remove the off-flavor of the mutant algae from the source, significantly improving the flavor and enhancing the product's storage stability.

Disclosed are methods of treating an eye disease by administering a recombinant adeno-associated virus (AAV) vector that encodes the proteoglycan decorin to the eye of a subject. Also provided are animal models of glaucoma that are generated using a recombinant AAV vector that encodes a constitutively active variant of transforming growth factor beta 2 (TGFβ2CS).

The present disclosure provides methods, compositions, and kits for the rapid release, labeling, and detection of O-glycans present on a glycoconjugate, such as a glycoprotein, glycopeptide, peptidoglycan, or proteoglycan of interest. The compositions and methods allow the released O-glycans to be subjected to high-throughput analysis.

The invention provides an application of OPO and a composition thereof in promoting intestinal development. The 1, 3-dioleoyl-2-palmitin disclosed by the invention can be used for up-regulating the transcriptional level of a coding gene gpc1 of phospholipid globulin glycan, a coding gene has1 of hyaluronic acid synthetase 1, a coding gene has2 of hyaluronic acid synthetase 2, a coding gene has3 of hyaluronic acid synthetase 3, a coding gene ext1 of exosome glycosyltransferase 1 and a coding gene ext2 of exosome glycosyltransferase 2; therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of oleanolic acid in promoting chondrogenic differentiation of chondrocytes. This invention discovers that oleanolic acid promotes the expression of proteoglycans and calcium deposition in ATDC5 cells undergoing chondrogenic differentiation, and also promotes the expression of ATDC5 cell chondrogenic differentiation markers. Therefore, it has the potential to be formulated into a drug that can promote chondrogenic differentiation of chondrocytes, thereby promoting cartilage repair and regeneration for the treatment of osteoarthritis and rheumatoid arthritis.

The invention relates to the technical field of medicines, and provides application of pulsatilla saponin B4 in preparation of a medicine for treating osteoarthritis. The pulsatilla saponin B4 can obviously promote the expression of SOX9, which is an important cartilage specific transcription factor, and inhibit the expression of matrix metalloproteinase 13 and disintegrin and metalloproteinase 5 with platelet reaction protein motifs at the same time, thereby finally relieving the degradation of extracellular cartilage matrixes such as II-type collagen and aggregation proteoglycan. Therefore, the pulsatilla saponin B4 can inhibit cartilage degeneration and improve cartilage extracellular matrix metabolic disorder. After the pulsatilla saponin B4 is injected into the abdominal cavity of a mouse with osteoarthritis, the progress of the osteoarthritis is effectively relieved, the side effect is relatively small, and no obvious injury is caused to main organs. The pulsatilla saponin B4 is applied to treatment of osteoarthritis, new application of the pulsatilla saponin B4 is developed, and a new choice is provided for preparation of the medicine for treating osteoarthritis.

A treated human umbilical cord composition for use in the treatment of Perony's disease by in vivo injection in a subject in need thereof using an effective amount of the composition. The composition comprises a water-based human umbilical cord filtrate, wherein endogenous hyaluronic acid (HA) and / or hyaluronic acid, fibronectin, insulin growth factor binding protein-1 (IGFBP-1), sulfated glycosaminoglycan (sGAG), exosomes, interleukin-1 receptor antagonist (IL-1ra), hepatocyte growth factor (HGF), transthyretin, metalloproteinase tissue inhibitor 1 (TIMP-1), and / or a pharmaceutically acceptable salt thereof in an amount effective to reduce the size of Pteroid disease plaques. The present invention relates to an aggregation glycan, or a combination thereof.

The application discloses a kind of preparation and application of microbial basic protein and adhesive proteoglycan hydrogel, belong to the field of biomaterials.Basic protein is extracted from microbial cells in the present application, using supramolecular assembly method, basic protein and acidic polysaccharide electrostatic assembly protein glycan gel material with strong tissue adhesion, the method is simple, widely available, and the cost is almost negligible.The tissue adhesive provided by the present application has immediate tissue adhesion performance, excellent biocompatibility and excellent antibacterial ability and hemostatic performance, which is beneficial to cope with different types of bleeding scene and irregular wound healing.Through cell compatibility and blood compatibility test, the results show that the material has excellent biocompatibility, and the basic protein has super strong bacteriostatic ability, avoids the invasion of foreign bacteria in the wound repair process, and has strong healing ability, greatly shortens the healing period of wound.

The invention discloses application of phentolamine in preparation of a medicine for treating intervertebral disc degeneration, and relates to the technical field of biomedicine.The phentolamine is applied to preparation of the medicine for treating intervertebral disc degeneration, inflammation inhibition, matrix expression promotion, matrix degradation inhibition and nucleus pulposus cell aging delaying are facilitated, and the effect of treating intervertebral disc degeneration is achieved. The height of the intervertebral disc can be increased, the integrity degree of a cell structure in the intervertebral disc can be improved, and the content of aggregation proteoglycan can be recovered.

The present invention discloses a method for constructing an animal model of ankylosing spondylitis and chronic enteritis. By using proteoglycan PG immune induction and sodium dextran sulfate chemical induction methods, an animal model is established that simulates the coexistence of ankylosing spondylitis and chronic enteritis in terms of symptoms, imaging changes, and pathological characteristics. The model mice exhibit imaging changes similar to those of human ankylosing spondylitis, such as sacroiliac joint bone erosion and sclerosis, narrowing and roughening of the joint space, and worm-eaten changes. Furthermore, they exhibit pathological changes similar to those of human chronic enteritis, such as intestinal epithelial cell destruction, glandular disorder, crypt structure destruction, goblet cell reduction, and inflammatory cell infiltration. This model can be used to study the interaction mechanism between the two diseases, explore new therapeutic targets, and help evaluate the potential application of new drugs in the treatment of ankylosing spondylitis and chronic enteritis, providing an important tool for mechanism research and drug development of such co-morbidities.

Provided is a method for analyzing proteoglycan, which enables simple analysis of proteoglycan in a sample.　Specifically, provided is a method for analyzing proteoglycan, comprising immersing or adding a sample containing proteoglycan into an aqueous solution containing a salt to obtain a liquid composition; and adding an alcohol to the liquid composition at a specific, relatively low concentration to obtain a purified precipitate, which is then subjected to proteoglycan analysis.

A bead-based assay system and methods for screening molecule inhibitors of protein-glycan interactions. The assay system includes at least one donor bead and at least one acceptor bead. A first molecule is coupled to the at least one donor bead. The first molecule comprises a protein. A second molecule is coupled to the at least one acceptor bead. The second molecule comprises a glycan. The bead-based assay system includes a screening molecule to be screened for inhibiting protein-glycan interactions. The screening molecule is enabled to interact at a protein-glycan interface of the first molecule and the second molecule.

The present application relates to the technical field of intervertebral disc degeneration treatment and drug delivery, and discloses an injectable oxynate sodium functionalized hydrogel microsphere loaded with TGFbeta3 and application, by loading glycolysis inhibitor SO in the GelMA microsphere matrix and post-adsorbing TGFbeta3, on the one hand, SO is used to inhibit the excessive active glycolysis in the degenerative microenvironment, reduce lactic acid accumulation and relieve inflammation, on the other hand, TGFbeta3 is used to effectively promote the synthesis of collagen and proteoglycan, both of which synergistically act from the two aspects of metabolic regulation and matrix synthesis, and jointly promote the recovery of intervertebral disc homeostasis, therefore, the oxynate sodium functionalized microsphere loaded with TGFbeta3 constructed by the present application can realize the synergistic treatment of multiple targets and multiple pathways by synchronously delivering metabolic regulators and synthesis promoters, so as to more effectively delay or reverse the intervertebral disc degeneration process, and finally achieve the beneficial effect of the double repair effect of simultaneously regulating abnormal glycolysis metabolism of degenerative nucleus pulposus cells and promoting extracellular matrix synthesis.

The invention relates to the technical field of glycopeptide preparation, and particularly provides a preparation method of soluble edible and medicinal fungus beta-glucan. Comprising the following steps: S1, carrying out pretreatment on liquid fermented mycelia, sporocarps of artificially cultivated edible and medicinal fungi or artificially cultivated mushroom bran mycelia; S2, carrying out enzymolysis on materials generated by pretreatment by adopting a protease reaction solution, depolymerizing the compact mycelia of the edible and medicinal fungi, sporocarps of the edible and medicinal fungi and cell wall proteoglycan protein complex tissues of the mycelia in the mushroom bran; s3, processing materials generated by enzymolysis; s4, carrying out enzymolysis on the proteoglycan protein compound suspension obtained in S3 by adopting a polysaccharide hydrolase reaction solution; according to the invention, an enzyme engineering technology and a modern separation technology are provided, macromolecular proteoglycan which is difficult to absorb and utilize is changed into smaller molecular glycopeptide, functional components in the mushroom liquid fermentation liquor are increased, and the content of effective components such as beta-glucan is increased.

The invention provides a preparation method and application of a dairy product for promoting development of an intestinal tract glycocalyx layer. Comprising a specific dose of casein phosphopeptides, and can up-regulate the transcriptional levels of a coding gene gpc1 of phospholipid globulin glycan, a coding gene has1 of hyaluronic acid synthetase 1, a coding gene has2 of hyaluronic acid synthetase 2, a coding gene has3 of hyaluronic acid synthetase 3, a coding gene ext1 of exosome glycosyltransferase 1 and a coding gene ext2 of exosome glycosyltransferase 2. Therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

This invention discloses a Chlorella heptapeptide TGPLGSR with multi-target lipid-lowering activity, its preparation method, and its applications. The amino acid sequence of this heptapeptide is Thr-Gly-Pro-Leu-Gly-Ser-Arg. The preparation method includes: performing ultraviolet and electroporation combined mutagenesis on wild-type Chlorella proteoglycans to obtain a high-protein-content mutant algal strain; obtaining algal protein through fermentation and synergistic extraction and purification with alcohols; directionally digesting the protein with alkaline protease, followed by enriching the active peptide components through ultrafiltration and gel chromatography; and finally, screening the heptapeptide using liquid chromatography-mass spectrometry (LC-MS), computer-aided prediction, and molecular docking techniques. This heptapeptide exhibits potent inhibitory activity against pancreatic lipase and can dose-dependently reduce the accumulation of triglycerides and cholesterol in 3T3-L1 cells. Its mechanism involves multiple target pathways, including inhibition of MMP-9, activation of AMPK phosphorylation, and downregulation of PNLIP, and it can be used to develop lipid-lowering functional foods or health products.

The present invention relates to the identification and use of tumor epitopes from subjects with brain cancer, and particularly to epitopes from brevican, neurocan, versican, and aggrecan and their use in formulating cancer vaccines for treatment of tumor patients. In some preferred embodiments the methods provide a means of identifying T cell epitopes in proteins upregulated in brain tumors and the selection of those peptides which can stimulate T cell responses in individual subjects with a particular combination of HLA alleles. It further identifies the T cell exposed motifs comprised in T cell epitopes and enables the design of peptides with alternative amino acids in positions other than the T cell exposed motifs. In preferred embodiments, the MHC I and MHC II alleles of the affected subject are determined, and peptides are selected which bind to their MHC molecules with a desired affinity to elicit stimulation.

The present invention provides a composition for treating osteoarthritis and its application, belonging to the technical field of medicine. The composition is composed of baicalin and α-ketoglutaric acid; the molar ratio of baicalin to α-ketoglutaric acid is 800:3-5. Within this specific ratio range, baicalin and α-ketoglutaric acid have a significant synergistic effect, and the treatment of osteoarthritis is achieved by protecting chondrocyte damage, alleviating cartilage fibrosis, and inhibiting the loss of cartilage proteoglycan and cartilage collagen fibers. Moreover, within the appropriate ratio range, it has the effect of reducing dosage and increasing efficacy for the treatment of osteoarthritis.

The present invention provides a novel method that can improve or maintain muscle quantity or muscle strength, and a novel method that can prevent obesity, or lower body fat percentage, or lower body fat quantity, or lower fat removal quantity. The proteoglycan used in the present invention is obtained by a method for producing the proteoglycan, comprising the steps of immersing a biological sample comprising the proteoglycan in an aqueous solution of a surfactant and collecting the solution after the immersion.

The invention relates to screening and application of a chronic kidney disease plasma protein marker, and belongs to the technical field of plasma protein markers. The protein marker combination comprises 25 proteins such as de-integrin metalloproteinase 22, keratinoin, chitosanase 3-like protein 1, an XVIII type collagen alpha 1 chain, a VI type collagen alpha 3 chain, a growth differentiation factor 15, phospholipid globulin glycan 1, a renal injury factor 1, histidine-rich calcium binding protein, kallikrein related peptidase 4 and the like which are positively correlated with the chronic kidney disease. The kit also comprises seven proteins such as a contact protein 5, an Erb-b2 receptor tyrosine kinase 3, an Erb-b2 receptor tyrosine kinase 4, an insulin-like growth factor binding protein 3 and the like which are negatively related to the chronic kidney disease. Compared with previous cross section research or case contrast research, the protein related to chronic kidney disease incidence can be screened, and the causal time sequence of the protein and chronic kidney disease is clearer.

The present disclosure provides an agent capable of reducing endotoxin and used for reducing endotoxin in animal tissue-derived proteoglycan, and a method for producing proteoglycan and capable of reducing endotoxin. The agent of the present disclosure for reducing endotoxin in the animal tissue-derived proteoglycan comprises a nonionic surfactant.

The invention discloses application of an IGF2BP2-m6A-VCAN-TLR2 (Insulin-like Growth Factor 2BP2-m6A-VCAN-TLR2) signal axis in preparation of a medicine for treating lymphatic metastasis of intrahepatic cholangiocarcinoma. Aiming at the problems of unknown lymphatic metastasis mechanism and lack of effective targets of intrahepatic cholangiocarcinoma, the invention discovers and verifies that mRNA binding protein 2 of insulin-like growth factor 2 is modified by m6A to regulate and control the expression of pluripotent proteoglycan so as to activate a Toll-like receptor 2 signal, promote macrophages to secrete vascular endothelial growth factor C and drive a brand new pathway of lymphatic metastasis. Based on this, the invention provides an inhibitor targeting the signal axis, especially a small molecule compound 8010-8498. Experiments show that the compound can significantly inhibit migration, invasion and epithelial-mesenchymal transition of bile duct cancer cells, reduce macrophage secretion of vascular endothelial growth factors C, effectively inhibit tumor growth and lymphatic metastasis in a nude mouse popliteal lymph node metastasis model and a spontaneous bile duct cancer model, and present a synergistic effect when combined with gemcitabine and cis-platinum.

The application relates to an anti-inflammatory and cartilage regeneration promoting material, a preparation method and application thereof, and belongs to the technical field of biomedical materials. The anti-inflammatory and cartilage regeneration promoting material comprises a PLGA (50:50) polymer material, and a huperzine A derivative dimer loaded on the PLGA (50:50) polymer material through 3D printing. The application also provides the use of the anti-inflammatory and cartilage regeneration promoting material in the preparation of anti-inflammatory, cartilage protection or cartilage regeneration promoting drugs. The PLGA / A10E scaffold has good biocompatibility, the PLGA / A10E scaffold degradation release liquid can effectively promote the differentiation of cartilage precursor cells into cartilage, and increase the formation of cartilage collagen matrix and cartilage proteoglycan. The in-vitro degradation liquid of the PLGA / A10E scaffold can promote the expression of SOX9 under non-inflammatory conditions; under LPS-mediated inflammatory conditions, the expression of MMP-13 can be inhibited, thereby promoting the synthesis of cartilage matrix and inhibiting the degradation of cartilage matrix.

The growth factor profile, connective tissue matrix constituents, and immunoprivileged status of urodele extracellular matrix (ECM) and accompanying cutaneous tissue, plus the presence of antimicrobial peptides there, render urodele-derived tissue an ideal source for biological scaffolds for xenotransplantation. In particular, a biological scaffold biomaterial can be obtained by a process that entails (A) obtaining a tissue sample from a urodele, where the tissue comprises ECM, inclusive of the basement membrane, and (B) subjecting the tissue sample to a decellularization process that maintains the structural and functional integrity of the extracellular matrix, by virtue of retaining its fibrous and on-fibrous proteins, glycoaminoglycans (GAGs) and proteoglycans, while removing sufficient cellular components of the sample to reduce or eliminate antigenicity and immunogenicity for xenograft purposes. The resultant urodele-derived biomaterial can be used to enhance restoration of skin homeostasis, to reduce the severity, durations and associated damage caused by post-surgical inflammation, and to promote progression of natural healing and regeneration processes. In addition, the biomaterial promotes the formation of remodeled tissue that is comparable in quality, function, and compliance to undamaged human tissue.